Stockreport

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

Solid Biosciences Inc.  (SLDB) 
Last solid biosciences inc. earnings: 8/14 07:25 am Check Earnings Report
US:NASDAQ Investor Relations: investors.solidbio.com/investor-relations
PDF - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia - - Dual route of admi [Read more]